Hanmi Pharmaceutical's board replaces CEO Park Jae-hyun and four directors, appointing HB Investment's Hwang Sang-yeon as new chief candidate amid ongoing management dispute between major shareholders and professional managers over company direction and founding principles.
#YonhapInfomax #HanmiPharmaceutical #CeoReplacement #HwangSangyeon #ManagementDispute #BoardRestructuring #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=109619
Hanmi Pharmaceutical Replaces CEO Park Jae-hyun, Names Hwang Sang-yeon as New Chief Candidate
Hanmi Pharmaceutical's board replaces CEO Park Jae-hyun and four directors, appointing HB Investment's Hwang Sang-yeon as new chief candidate amid ongoing management dispute between major shareholders and professional managers over company direction and founding principles.
Hanmi Pharmaceutical Co. is set to maintain double-digit ROE through next year, driven by a 97% proprietary drug portfolio, robust subsidiary performance, and stable financials, though regulatory risks remain.
#YonhapInfomax #HanmiPharmaceutical #ROE #ProprietaryDrugs #OperatingProfit #FinancialStructure #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=103716
Hanmi Pharmaceutical Maintains Double-Digit ROE—Will Capital Efficiency Excellence Continue Through Next Year
Hanmi Pharmaceutical Co. is set to maintain double-digit ROE through next year, driven by a 97% proprietary drug portfolio, robust subsidiary performance, and stable financials, though regulatory risks remain.
Hanmi Pharmaceutical has signed an exclusive deal to export its GLP-1 obesity drug and diabetes treatments to Mexico’s largest private pharma firm, expanding its global reach in metabolic disease therapies.
#YonhapInfomax #HanmiPharmaceutical #Efpeglenatide #LaboratoriosSanfer #GLP1 #DiabetesTreatment #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=102383
Hanmi Pharmaceutical Exports Obesity Drug to Mexican Pharma Firm
Hanmi Pharmaceutical has signed an exclusive deal to export its GLP-1 obesity drug and diabetes treatments to Mexico’s largest private pharma firm, expanding its global reach in metabolic disease therapies.
The JP Morgan Healthcare Conference spotlighted AI-biotech convergence, fierce obesity drug competition, South Korean biosimilar firms' new drug push, and Hanmi Pharmaceutical's share plunge, underscoring global shifts in pharma innovation and market dynamics.
#YonhapInfomax #JPmorganHealthcare #ArtificialIntelligence #ObesityDrugs #HanmiPharmaceutical #BiosimilarDevelopment #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=100312
JP Morgan Healthcare Conference Highlights—AI Integration and Intensifying New Drug Race
The JP Morgan Healthcare Conference spotlighted AI-biotech convergence, fierce obesity drug competition, South Korean biosimilar firms' new drug push, and Hanmi Pharmaceutical's share plunge, underscoring global shifts in pharma innovation and market dynamics.
Hanmi Pharmaceutical has received regulatory approval to begin a Phase 2 clinical trial of its targeted melanoma drug Belvarafenib, aiming to address unmet needs in cancer treatment with a combination therapy for patients with NRAS-mutant melanoma.
#YonhapInfomax #HanmiPharmaceutical #Belvarafenib #Melanoma #ClinicalTrial #NRASMutation #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=99004
Hanmi Pharmaceutical Initiates Phase 2 Clinical Trial for Melanoma Drug
Hanmi Pharmaceutical has received regulatory approval to begin a Phase 2 clinical trial of its targeted melanoma drug Belvarafenib, aiming to address unmet needs in cancer treatment with a combination therapy for patients with NRAS-mutant melanoma.
Hanmi Pharmaceutical has signed an exclusive supply and licensing agreement with Vietpop to export its hypertension combination drug to Vietnam, aiming to expand access to treatment and address unmet medical needs in the local market.
#YonhapInfomax #HanmiPharmaceutical #Vietpop #HypertensionCombinationDrug #VietnamMarket #SupplyAgreement #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=89278
Hanmi Pharmaceutical Signs Supply Agreement with Vietpop, Bringing Hypertension Combination Drug to Vietnam
Hanmi Pharmaceutical has signed an exclusive supply and licensing agreement with Vietpop to export its hypertension combination drug to Vietnam, aiming to expand access to treatment and address unmet medical needs in the local market.
Hanmi Science Co. reported a 75.2% year-on-year surge in Q3 operating profit to 39.3 billion won, driven by strong healthcare and pharmaceutical distribution sales, while key subsidiary Hanmi Pharmaceutical advanced global competitiveness through new drug developments and international partnerships.
#YonhapInfomax #HanmiScience #OperatingProfit #HealthcareBusiness #HanmiPharmaceutical #Q3Earnings #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=87930
Hanmi Science Posts 75.2% Surge in Q3 Operating Profit to 39.3 Billion Won—Driven by Healthcare and Distribution Gains (Comprehensive)
Hanmi Science Co. reported a 75.2% year-on-year surge in Q3 operating profit to 39.3 billion won, driven by strong healthcare and pharmaceutical distribution sales, while key subsidiary Hanmi Pharmaceutical advanced global competitiveness through new drug developments and international partnerships.
Hanmi Pharmaceutical Unveils Blockbuster Products at World's Largest Pharmaceutical Expo
Hanmi Pharmaceutical will showcase its blockbuster drugs and innovative pipeline at CPHI Worldwide 2025 in Frankfurt, highlighting its global CDMO capabilities and FDA-approved biologic Rolontis.
Hanmi Pharmaceutical Shares Surge 26% on Positive Obesity Drug Trial Results—Analysts Caution Overheated R&D Expectations
Hanmi Pharmaceutical shares surged 26% after positive Phase 3 obesity drug results, boosting R&D optimism, though analysts warn of overheating amid upcoming clinical milestones.
Hanmi Science and Hanmi Pharmaceutical have both been upgraded to 'AA-' by NICE Investors Service, reflecting robust financial health and industry-leading competitiveness in South Korea's pharmaceutical sector.
#YonhapInfomax #HanmiScience #HanmiPharmaceutical #NICEInvestorsService #CreditRating #FinancialStability #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket https://en.infomaxai.com/news/articleView.html?idxno=85224
Hanmi Science and Hanmi Pharmaceutical Secure 'AA-' Rating—'Industry's Highest Level'
Hanmi Science and Hanmi Pharmaceutical have both been upgraded to 'AA-' by NICE Investors Service, reflecting robust financial health and industry-leading competitiveness in South Korea's pharmaceutical sector.
Yonhap Infomax News